The diabetes drug market continues to be a street fight between major pharmaceutical companies like Sanofi (NYSE: SNY ) , Novo Nordisk (NYSE: NVO ) , and Lilly (NYSE: LLY )
. Considering that about $45 billion a year in spent on therapeutic
agents for diabetes (drugs and insulin), it's no wonder why these
companies compete so aggressively and look to gain labeling advantages
through their clinical trials.
This year's American Diabetes Association annual meeting has
come and gone, with not a lot in the way of market-shifting events.
Sanofi comes out of the meeting looking a little weaker, Novo a little
stronger, and Lilly looks like the most aggressive player in the space.
Continue here:
Who Will Win This $45 Billion Market?
No comments:
Post a Comment